Skip to content
Search for:
About us
Overview
History
Management Board
Ethical management
Areas of Partnership
Location
Core Technology
NexP™ Fusion Technology
NexMab™ ADC Technology
Biosimilars
Technological Outcomes
Pipeline
Overview
Project
ALT-P1
ALT-Q2
Project
ALT-P7
ALT-Q5
Project
ALT-L9
ALT-L2
ALT-LS2
ESG
ESG introduction
ESG introduction
ESG Goal
ESG Guide line
Environmental
Environmental management
Safety and Health management
Introduction
Social
Charter
Counseling Center
Consultation Application
Board of directors
Board of directors
Audit System
Compliance Management
Ethics Charter
IR
News
Reports
Notices
Career
Whom Alteogen is Looking for
Job Notice
로그인
한국어
Loading...
News
alteogen
2018-04-27T13:47:37+09:00
News
Reports
Notices
News
Number
Title
Author
Date
27
Alteogen Inc. obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
alteogen
|
2019.05.22
|
Votes 0
|
Views 2379
alteogen
2019.05.22
26
Alteogen applies for P1 trial for Eylea biosimilar
alteogen
|
2019.02.28
|
Votes 0
|
Views 1489
alteogen
2019.02.28
25
Alteogen Inc. Becomes First Mover for Eylea Biosimilar with securing global competitiveness by registering patent
alteogen
|
2019.01.04
|
Votes 0
|
Views 1621
alteogen
2019.01.04
24
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
alteogen
|
2018.12.04
|
Votes 0
|
Views 1512
alteogen
2018.12.04
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen
|
2018.08.17
|
Votes 0
|
Views 1324
alteogen
2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen
|
2018.08.07
|
Votes 0
|
Views 1208
alteogen
2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen
|
2018.07.30
|
Votes 0
|
Views 965
alteogen
2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen
|
2018.07.11
|
Votes 0
|
Views 1056
alteogen
2018.07.11
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen
|
2018.07.04
|
Votes 0
|
Views 850
alteogen
2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen
|
2018.05.28
|
Votes 0
|
Views 1122
alteogen
2018.05.28
1
2
3
»
Last
All
Title
Content
Author
Search
Go to Top